Greenwich LifeSciences, Inc. (GLSI) Stock

Greenwich LifeSciences, Inc. (GLSI) is a Healthcare stock trading at $16.64 (as of 2026-08-21), with a market capitalization of $244.32M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies for breast cancer and other cancers that express HER2/neu. Its lead program, GP2, is an immunotherapy intended to help prevent breast cancer recurrences in patients who have undergone surgery.

Understand Greenwich LifeSciences, Inc.: how it makes money

Greenwich LifeSciences develops novel cancer immunotherapies, including its GP2 program aimed at preventing breast cancer recurrences in patients with HER2/neu-expressing cancers, and it is currently operating as a clinical-stage biopharma with no demonstrated operating profitability.

As a clinical-stage biopharma, its profit model is not yet driven by recurring product revenue, it is driven by whether clinical progress can lead to future commercialization or partnering, while near-term results are constrained by ongoing operating losses.

Business quality (Unprofitable): Unprofitable (operating margin -8344%)

Bull case

  • Phase IIb progress supports validation: Its lead candidate GP2 completed a Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. This is meaningful development progress because it moves the program beyond early-stage discovery into later-stage clinical evidence.

Bear case

  • Deep operating losses constrain options: The latest period shows an operating margin -8344%, reflecting heavy unprofitability. That level of ongoing losses can make the business more dependent on continued financing and increases the risk that delays in clinical or commercialization paths could pressure resources.
Valuation — source: SEC EDGAR (first-party)
Price$16.64
Market Cap$244.32M
Price / Book46.36
Price / Sales1795.68
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$89700.00
Net Margin-21581.1%
Revenue Growth (YoY)-59.8%
EPS Growth (YoY)18.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-4.88 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($10.42M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSnehal S. Patel
Employees4
CountryUS
IPO Date2020-09-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • MacroGenics, Inc. (MGNX)
  • Pyxis Oncology, Inc. (PYXS)
  • Nature's Sunshine Products, Inc. (NATR)
  • Akebia Therapeutics, Inc. (AKBA)
  • Sionna Therapeutics, Inc. (SION)
  • Whitehawk Therapeutics Inc (WHWK)
  • Organogenesis Holdings Inc. (ORGO)
  • Minerva Neurosciences, Inc. (NERV)
GLSI earnings history · GLSI institutional & insider holders · GLSI KPIs & operating metrics · GLSI financials · GLSI investor presentations & press releases · GLSI SEC filings · GLSI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.